Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Acambis is a leading biotechnology company targeting infectious diseases with novel vaccines. Acambis’ development-stage pipeline includes vaccines that could either offer improvements over existing products or target unmet medical needs. Its investigational vaccine against Japanese encephalitis, ChimeriVax-JE, which is undergoing Phase 3 clinical testing, is intended to provide an “ideal” vaccine to address the estimated 50,000 cases of this viral disease in Asia every year. Acambis’ proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile ( www.acambis.com )
Acambis plc
Powerhouse Technology Pk 100 Fulbourn Rd
Cambridge, CB1 9PT
United Kingdom
Tel: +44 1223 275300
Fax: +44 1223 416300